Randomized phase II study of two different schedules of gemcitabine and oral S-1 in chemo - naïve patients with <font color="blue">advanced_1</font> <font color="blue">non_1</font> <font color="blue">-_1</font> <font color="blue">small_1</font> <font color="blue">cell_1</font> <font color="blue">lung_1</font> <font color="blue">cancer_1</font> <font color="blue">._1</font> 
<br>
<br> INTRODUCTION This study was conducted to evaluate the <font color="blue">efficacy_2</font> <font color="blue">and_2</font> <font color="blue">safety_2</font> and to <font color="blue">compare_1</font> <font color="blue">dosing_1</font> <font color="blue">schedules_1</font> of gemcitabine combined with S-1 in chemo - naïve non - small cell lung cancer patients . 
<br> METHODS Patients with chemo - naïve stage IIIB / IV non - small cell lung cancer were randomized into two treatment arms . Patients were given oral S-1 ( 60 mg / m / d , twice a day ) from days 1 to 14 with gemcitabine ( 1000 mg / m / d ) on days 1 and 8 ( arm A ) or on days 8 and 15 ( arm B ) . This cycle was repeated every 21 days . 
<br> RESULTS A total of 80 patients were entered in this trial . The primary end point of this study was <font color="blue">response_2</font> <font color="blue">rate_2</font> <font color="blue">._2</font> The <font color="blue">response_2</font> <font color="blue">rates_2</font> of arm A and arm B were 22.0 and 28.9% , respectively ( p = 0.606 ) . <font color="blue">Median_1</font> <font color="blue">time_2</font> <font color="blue">to_2</font> <font color="blue">treatment_2</font> <font color="blue">failure_2</font> in arm A was 3.6 months and 4.8 months in arm B. <font color="blue">Median_1</font> <font color="blue">time_2</font> <font color="blue">to_2</font> <font color="blue">progression_2</font> in arm A was 4.1 months and 5.5 months in arm B. <font color="blue">Median_1</font> <font color="blue">survival_2</font> <font color="blue">time_2</font> in arm A and arm B was 15.5 months and 18.8 months , respectively . <font color="blue">The_1</font> <font color="blue">toxicity_3</font> <font color="blue">profile_3</font> was <font color="blue">relatively_1</font> <font color="blue">mild_1</font> and <font color="blue">did_1</font> <font color="blue">not_1</font> <font color="blue">differ_1</font> very much between two arms . 
<br> CONCLUSION The <font color="blue">combination_1</font> <font color="blue">of_1</font> <font color="blue">gemcitabine_1</font> <font color="blue">and_1</font> <font color="blue">S-1_1</font> <font color="blue">was_1</font> <font color="blue">determined_1</font> <font color="blue">to_1</font> <font color="blue">be_1</font> <font color="blue">feasible_2</font> <font color="blue">and_2</font> <font color="blue">effective_2</font> <font color="blue">for_2</font> <font color="blue">advanced_2</font> <font color="blue">non_2</font> <font color="blue">-_2</font> <font color="blue">small_2</font> <font color="blue">cell_2</font> <font color="blue">lung_2</font> <font color="blue">cancer_2</font> <font color="blue">._2</font> We selected arm B for further studies because of its <font color="blue">higher_1</font> <font color="blue">response_3</font> <font color="blue">rate_3</font> <font color="blue">and_2</font> <font color="blue">survival_3</font> <font color="blue">data_3</font> <font color="blue">._3</font>